Essential Healthcare News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.

Press releases published on June 7, 2026

Jun. 7, 2026

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Indeterminate GlobeNewswire

Jun. 7, 2026

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

Indeterminate GlobeNewswire

Jun. 7, 2026

Through the Scope: Living With Paranoid Schizophrenia and PTSD Shares a Raw Account of Invisible War and Survival

Indeterminate EIN Presswire

Jun. 7, 2026

30,000 Participants Report Recurring Dream and Intuitive Experiences

Indeterminate EIN Presswire

Jun. 7, 2026

30,000人以上が報告する「鮮明な夢」「直感の向上」「人生の変化」― 日本人ホリスティックヒーラーNOCCIが意識と夢の可能性について探究を呼びかけ

Indeterminate EIN Presswire

Jun. 7, 2026

Blue Star Mothers of America Highlights PTSD Awareness Month and Support for Military Families

Indeterminate EIN Presswire

Jun. 7, 2026

Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes

Indeterminate GlobeNewswire

Jun. 7, 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

Indeterminate GlobeNewswire

Jun. 7, 2026

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Indeterminate GlobeNewswire

Jun. 7, 2026

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Indeterminate GlobeNewswire